Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 4/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2970801 | 0.79 | TSHR (0.35) | TSHR | |
| SCHEMBL2962205 | 0.78 | ALDH1A1 (0.44) | TSHR | |
| SCHEMBL11683236 | 0.65 | TSHR (0.50) | TSHR | |
| SCHEMBL2964693 | 0.64 | DAPK3 (0.41) | DAPK3ROCK2CHEK2PIM1PLK1 | |
| SCHEMBL27005158 | 0.63 | TSHR (0.43) | TSHR | |
| SCHEMBL560581 | 0.61 | TSHR (0.39) | TSHR | |
| SCHEMBL6261212 | 0.61 | DAPK3 (0.48) | IDH1DAPK3ROCK2CHEK2PIM1 | |
| SCHEMBL1931582 | 0.59 | RORC (0.36) | TSHR | |
| SCHEMBL19235998 | 0.59 | CA1 (0.42) | TSHR | |
| SCHEMBL15507554 | 0.58 | NPC1 (0.43) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8212078-B2 | Making chain extenders with slower cure rates; reacting a ketone and/or aldehyde with a primary amine in the presence of an acidic ion exchange resin and hydrogenation agent; making diimine same way but excluding hydrogenation agent; e.g. N,N'-di-5-nonyl-isophoronediamine | ALBEMARLE CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-7767858-B2 | Diimines and secondary diamines | ALBEMARLE CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| EP-2143707-A2 | Secondary diamine | Albermarle Corporation (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080315155-A1 | Diamines Having Reduced Color | ALBEMARLE CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080262187-A1 | Blends of Diamines Having Reduced Color | ALBEMARLE CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080194788-A1 | Diimines and Secondary Diamines | ALBEMARLE CORPORATION (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080033210-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-01-03 | — | — | US | disclosed |
| EP-1868987-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7288677-B2 | Diimines and secondary diamines | ALBEMARLE CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| WO-2006104528-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060217567-A1 | Diimines and secondary diamines | ALBEMARLE CORPORATION | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | DDT, DDC, AOC1 | IDH1 29/4885DAPK3 529/4885ROCK2 1947/4885 |
| US-20080262187-A1 | Blends of Diamines Having Reduced Color | DDT, DDC, AOC1 | IDH1 133/4885DAPK3 3660/4885ROCK2 3818/4885 |
| US-20080033210-A1 | DIIMINES AND SECONDARY DIAMINES | DDT, DDC, AOC1 | IDH1 29/4885DAPK3 529/4885ROCK2 1947/4885 |
| US-20080315155-A1 | Diamines Having Reduced Color | DDT, DPYD, DDC | IDH1 95/4885DAPK3 2846/4885ROCK2 4349/4885 |
| US-20080194788-A1 | Diimines and Secondary Diamines | DDT, DDC, AOC1 | IDH1 16/4885DAPK3 775/4885ROCK2 1879/4885 |
| US-20060217567-A1 | Diimines and secondary diamines | DDT, DDC, AOC1 | IDH1 29/4885DAPK3 529/4885ROCK2 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.